» Articles » PMID: 22051332

Impaired Natriuretic and Renal Endocrine Response to Acute Volume Expansion in Pre-clinical Systolic and Diastolic Dysfunction

Abstract

Objectives: We hypothesized an impaired renal endocrine and natriuretic response to volume expansion (VE) in humans with pre-clinical systolic dysfunction (PSD) and pre-clinical diastolic dysfunction (PDD). We further hypothesized that exogenous B-type natriuretic peptide (BNP) could rescue an impaired natriuretic response in PSD and PDD.

Background: Recent reports suggest that in early systolic heart failure (HF), there is an impaired natriuretic response to acute VE.

Methods: PSD was defined as left ventricular ejection fraction <40% without HF symptoms. PDD was defined as ejection fraction >50%, moderate to severe diastolic dysfunction by Doppler criteria, and no HF symptoms. A double-blinded, placebo-controlled, crossover study was employed to determine the renal response to VE (0.25 ml/kg/min of normal saline for 60 min) in the presence and absence of exogenous BNP. Twenty healthy control subjects, 20 PSD subjects, and 18 PDD subjects participated.

Results: In healthy control subjects, urinary cyclic guanosine monophosphate (cGMP) and natriuresis increased after VE. In contrast, among PSD and PDD subjects, there was a paradoxical decrease in urinary cGMP and attenuated natriuresis. Pre-treatment with subcutaneous BNP resulted in similar increases in both urinary cGMP and natriuresis among healthy normal, PSD, and PDD subjects.

Conclusions: In PSD and PDD, there is impaired renal cGMP activation, which contributes to impaired natriuresis in response to VE. Impaired activation of urinary cGMP and reduced natriuresis may contribute to volume overload and the progression of HF among PSD and PDD subjects. Importantly, the impaired renal excretory response to VE is rescued by exogenous BNP in PSD and PDD.

Citing Articles

Effect of Sacubitril/Valsartan or Enalapril on Left Ventricular Function in Patients With Hematologic Malignancies Treated With Bone Marrow Transplantation: A Randomized Controlled Trial.

Katogiannis K, Ikonomidis I, Farmakis D, Thymis J, Stamouli M, Koliou G JACC Adv. 2025; 4(3):101628.

PMID: 39983618 PMC: 11891692. DOI: 10.1016/j.jacadv.2025.101628.


Renal Effects of Combination Phosphodiesterase V Inhibition and Low-Dose B-Type Natriuretic Peptide in Acute Heart Failure: A Randomized Clinical Trial.

Hubers S, Benike S, Johnson B, McKie P, Scott C, Chen H Circ Heart Fail. 2024; 17(12):e011761.

PMID: 39513267 PMC: 11653223. DOI: 10.1161/CIRCHEARTFAILURE.124.011761.


Effect of Post-Loop Diuretic Urinary Sodium Level on Length of Stay and Rehospitalization in Acutely Decompensated Heart Failure Patients.

Soerarso R, Hasanah D, Yonas E, Tawari F, Raharjo S, Siswanto B Cardiol Res. 2024; 15(5):350-357.

PMID: 39420977 PMC: 11483111. DOI: 10.14740/cr1696.


Fluid Restriction for Patients with Heart Failure: Current Evidence and Future Perspectives.

Kato N, Nagatomo Y, Kawai F, Kitai T, Mizuno A J Pers Med. 2024; 14(7).

PMID: 39063995 PMC: 11277838. DOI: 10.3390/jpm14070741.


SGLT-2 Inhibitors: Potential Novel Strategy to Prevent Congestive Heart Failure in Diabetes?.

Verbrugge F, Vangoitsenhoven R, Mullens W, Van der Schueren B, Mathieu C, Tang W Curr Cardiovasc Risk Rep. 2024; 9(8).

PMID: 38994329 PMC: 11238646. DOI: 10.1007/s12170-015-0467-0.


References
1.
Vasan R, Benjamin E, Levy D . Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. J Am Coll Cardiol. 1995; 26(7):1565-74. DOI: 10.1016/0735-1097(95)00381-9. View

2.
Yusuf S, Pitt B, Davis C, Hood Jr W, Cohn J . Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992; 327(10):685-91. DOI: 10.1056/NEJM199209033271003. View

3.
Oliver P, Fox J, Kim R, Rockman H, Kim H, Reddick R . Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. Proc Natl Acad Sci U S A. 1998; 94(26):14730-5. PMC: 25105. DOI: 10.1073/pnas.94.26.14730. View

4.
Redfield M, Jacobsen S, Burnett Jr J, Mahoney D, Bailey K, Rodeheffer R . Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003; 289(2):194-202. DOI: 10.1001/jama.289.2.194. View

5.
Abhayaratna W, Marwick T, Smith W, Becker N . Characteristics of left ventricular diastolic dysfunction in the community: an echocardiographic survey. Heart. 2006; 92(9):1259-64. PMC: 1861192. DOI: 10.1136/hrt.2005.080150. View